Strattera side effects

What side effects can Atomoxetine have?

Below you will find the most important information about possible, known side effects of Atomoxetine.
These side effects do not occur, but you can. Because every person reacts differently to medication. Please also note that the type and frequency of side effects may vary depending on the drug formulation (eg tablet, syringe, ointment).

Very common side effects:
Appearance loss, headache, drowsiness, abdominal pain, nausea and vomiting.

Common side effects:
loss of appetite, irritability, mood swings, insomnia, dizziness, constipation, indigestion, dermatitis, rash, fatigue, lack of drive, weight loss, blood pressure increase.

Occasional side effects:
Suicidal tendencies, suicide attempts, aggression, hostility, mood swings, insomnia, fainting, trembling, migraine, pupil dilation, palpitations, tachycardia, itching, increased perspiration, allergic reactions, weakness.

Adverse reactions without frequency:
psychosis (including delusions), excitement, seizures, arrhythmia (QT interval prolongation), circulatory disorders of fingers and toes (Raynaud’s syndrome), increased blood liver value, jaundice, hepatitis, Urinary delay, urinary retention, diseased penis stiffness (priapism), penile pain, testicular pain.

Special features:
In studies of children and adults, atomoxetine patients showed an increase in heart rate and increases in blood pressure compared to placebo. The condition of the heart and blood vessels must therefore be regularly monitored by a doctor. The values of blood pressure and pulse should be recorded and evaluated after each dose change and then at least every six months. Patients experiencing symptoms suggestive of heart disease during their atomoxetine treatment must be promptly screened by a cardiologist.

What interactions does atomoxetine show?

Please note that the interactions may vary depending on the drug formulation of a drug (eg tablet, syringe, ointment).

Atomoxetine must not be used in combination with antidepressants from the MAO inhibitor group. Therapy with a MAO inhibitor must be completed for at least two weeks before Atomoxetine may be used. Atomoxetine must also be discontinued for at least two weeks before starting treatment with a MAO inhibitor.

Selective serotonin reuptake inhibitors such as fluoxetine and paroxetine (for depression), the cardiac quinidine and the fungal terbinafine inhibit the breakdown of atomoxetine, increase its activity and increase the risk of cardiac arrhythmia. When combined with such agents, the physician must adjust the dose and take slower dose escalation. This is especially true for people who metabolize Atomoxetine anyway delayed.

If asthma patients are treated with high doses of beta-2-sympathomimetics (especially salbutamol) in the form of an asthma spray, oral or injectable, atomoxetine should be used with caution as it enhances the effect of salbutamol on the cardiovascular system. Heart palpitations and hypertension can occur.

All drugs with effects on the heart rhythm are risky along with atomoxetine. Neuroleptics, Class I and III antiarrhythmics, the antibiotics moxifloxacin and erythromycin, the drug-replacement drugs methadone, mefloquine (for malaria), tricyclic antidepressants and lithium (for depression) or the gastric agent cisapride, together with atomoxetine, can cause cardiac arrhythmias. The same applies to active ingredients such as dehydrating agents from the group of thiazides, which disturb the mineral balance in the blood.

Directly or indirectly antihypertensive agents (such as salbutamol) should be used with caution in combination with atomoxetine, as excessive blood pressure may increase. Conversely, Atomoxetine can counteract the effect of hypotensives.

Atomoxetine alone can cause seizures in the brain. In combination with antidepressants, neuroleptics, mefloquine, bupropion (for smoking cessation and for depression) or tramadol (opioid analgesic), this risk increases additionally.

Substances with an effect on the neurotransmitter norepinephrine should be used with caution when administering atomoxetine. The effects can namely add up adversely. Examples are antidepressants such as imipramine, venlafaxine and mirtazapine or mucosal decongestants such as pseudoephedrine or phenylephrine.

Potential Strattera side effects may include: